One of the most common questions patients ask before starting semaglutide — or while on it — is about dosing. Not just "how much" but "how long at each step," "what happens if I feel sick," and "when do I know if I should move up."
The answers are in the FDA-approved titration schedules. Both Ozempic (semaglutide for type 2 diabetes) and Wegovy (semaglutide for weight management) use a stepped approach that starts low and increases gradually. The same is true for Mounjaro and Zepbound (tirzepatide). The schedule isn't arbitrary — it's specifically designed to minimize gastrointestinal side effects while building to an effective dose.
Understanding how the schedule works takes away a lot of the anxiety around it. Here are the three main protocols, explained clearly.
Why Titration Exists: The Logic Behind the Stepped Approach
Semaglutide's most common side effects — nausea, vomiting, diarrhea — are dose-dependent. They peak during dose escalation and tend to diminish once you stay at a stable dose for a few weeks. The 4-week-per-step schedule in both the Ozempic and Wegovy labels exists to give your body time to adapt before the next increase.
The starting doses (0.25 mg for Ozempic/Wegovy, 2.5 mg for Mounjaro/Zepbound) are not intended to be the doses you stay on long-term. They are loading doses — sub-therapeutic amounts that allow your GI system to adjust before the medication reaches clinically effective levels. This is why many patients feel minimal appetite suppression in the first few weeks. That is normal and expected.
Key principle: The titration schedule is a maximum speed, not a minimum requirement. If you are not tolerating a dose well after 4 weeks, your physician may choose to hold you at that dose for additional weeks rather than escalating. There is no requirement to increase on schedule.
Ozempic (Semaglutide) Dosage Schedule
Ozempic is FDA-approved for type 2 diabetes. Its maximum dose (2 mg/week) is higher than the lowest dose but lower than Wegovy's maximum. The four-step titration takes most patients 16 weeks to complete to the target dose.
| Dose | Duration at Each Step | Purpose | Notes |
|---|---|---|---|
| 0.25 mg/week | 4 weeks | Initial tolerability phase | Starting dose. Appetite effect is minimal at this level. This is not a therapeutic dose — it is a loading dose. |
| 0.5 mg/week | 4+ weeks | Therapeutic entry dose | Many patients find this dose effective. Move up only if weight loss or glycemic control is insufficient and side effects are manageable. |
| 1 mg/week | 4+ weeks (or ongoing) | Standard therapeutic dose | Common maintenance dose for diabetes management. Most patients see meaningful HbA1c reduction and weight loss at this level. |
| 2 mg/week | Ongoing (if tolerated) | Maximum Ozempic dose | Only if glycemic targets are not met at 1 mg and the medication is well-tolerated. Not approved for weight management alone. |
Ozempic is administered as a single weekly subcutaneous injection, on the same day each week. The injection can be given in the abdomen, thigh, or upper arm. Rotating injection sites within the same body region reduces injection-site discomfort.
Wegovy (Semaglutide 2.4 mg) Dosage Schedule
Wegovy contains the same molecule as Ozempic (semaglutide) but is FDA-approved specifically for chronic weight management and goes up to a higher dose of 2.4 mg/week. The five-step titration takes most patients 20 weeks to reach the maximum dose.
| Dose | Duration at Each Step | Purpose | Notes |
|---|---|---|---|
| 0.25 mg/week | 4 weeks | Initial tolerability phase | Same starting dose as Ozempic. Allow full adaptation before escalating. |
| 0.5 mg/week | 4 weeks | Early therapeutic phase | Appetite suppression typically becomes noticeable. Some patients stabilize here. |
| 1 mg/week | 4 weeks | Mid-range therapeutic dose | Weight loss typically accelerates at this dose. GI side effects may increase slightly. |
| 1.7 mg/week | 4 weeks | High-range dose | Significant weight loss expected. Monitor for side effects — this is where GI tolerability becomes more variable. |
| 2.4 mg/week | Ongoing (maintenance) | Maximum Wegovy dose | Clinical trial target dose. Used in STEP 1 and all major weight-loss trials. This is the dose that produced the ~15% average body weight loss in STEP 1. |
Wegovy comes in five separate injection pens, each delivering a different dose. The pens are color-coded and labeled by dose, making it difficult to confuse doses — a practical safety feature built into the delivery system.
Ready to Start — or Adjust Your Dose?
A board-certified physician will review your current treatment status and explain your options — including whether dose adjustment or a different medication may be appropriate for your goals.
Discuss with a Certified PrescriberNo commitment · Physician-reviewed · Results may vary
Mounjaro (Tirzepatide) Dosage Schedule
Tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight management — works on two receptor types (GLP-1 and GIP) rather than one, which changes the efficacy profile. The titration schedule has six steps, starting higher than semaglutide and reaching a maximum of 15 mg/week.
| Dose | Duration at Each Step | Purpose | Notes |
|---|---|---|---|
| 2.5 mg/week | 4 weeks | Starting/loading dose | Intentionally sub-therapeutic. Patients typically do not feel strong appetite effects at this dose — this is normal. The 2.5 mg dose is not intended for long-term use. |
| 5 mg/week | 4+ weeks | Therapeutic entry dose | Appetite suppression becomes more pronounced. Meaningful weight loss and HbA1c reduction typically begin at this dose. |
| 7.5 mg/week | 4+ weeks | Mid-range dose | Further increase in efficacy. Some patients experience increased GI side effects at this step. |
| 10 mg/week | 4+ weeks | High-range dose | Significant weight loss expected. Monitoring for tolerability is important — this is where side effects are most pronounced in some patients. |
| 12.5 mg/week | 4+ weeks | Near-maximum dose | Most patients see robust results at this level. Side effects should be monitored closely, particularly GI tolerability. |
| 15 mg/week | Ongoing (maintenance) | Maximum Mounjaro/Zepbound dose | Maximum approved dose. In SURMOUNT-1, the 15 mg dose produced ~22.5% average body weight loss — the highest of any approved GLP-1 medication. Consider this dose the clinical target if tolerated. |
How Mounjaro/Zepbound differs from semaglutide: Because tirzepatide activates both GLP-1 and GIP receptors, it produces a stronger overall effect on appetite suppression and blood sugar regulation at lower doses than semaglutide. The two medications are not interchangeable and should not be compared dose-for-dose.
Side Effects by Dose Level: What to Expect as You Escalate
Side effects on GLP-1 medications are not static — they follow the dose. Understanding the pattern helps you anticipate what's normal and when to contact your physician.
0.25 – 0.5 mg (Starting Phase)
Most likely: mild nausea, reduced appetite, fatigue. Typically peaks in weeks 1–2 then improves. Many patients feel very little medication effect at these doses — this is expected.
1 – 1.7 mg (Mid-Dose)
Appetite suppression is usually noticeable. GI effects (nausea, constipation or diarrhea) may increase. Fatigue often diminishes. This is where most patients find the medication "starts working."
2 – 2.4 mg / 10 – 15 mg (High Dose)
Maximum appetite suppression. GI side effects most pronounced at this level — nausea and constipation are most common. Some patients plateau in side effects; others need dose adjustment. Monitor closely during first 4 weeks at max dose.
For a full breakdown of side effects and management strategies, see our guide: Semaglutide Side Effects: What to Expect and How to Manage Them.
What to Do If You Miss an Injection: FDA Guidance
Missing a weekly injection occasionally happens. Here's what the FDA labeling says you should do, depending on how late the missed dose is:
| Time Since Missed Dose | What to Do | Rationale |
|---|---|---|
| Within 5 days of scheduled dose | Inject the missed dose as soon as possible, then continue your regular weekly schedule | The drug's half-life supports this window. Taking it late still maintains adequate plasma levels. Resume normal schedule from the day you inject. |
| More than 5 days after scheduled dose | Skip the missed dose. Resume your regular schedule on your next scheduled day. | Skipping avoids the risk of double-dosing and the nausea that would follow a large bolus of medication after a gap. Do not "catch up" by taking two doses. |
Important: If more than 5 days have passed, do not take two doses in one week to "catch up." This significantly increases the risk of severe nausea, vomiting, and dehydration. The gap in your schedule means your body has adapted to lower drug levels — a double dose after a gap can be rough. Skip the missed dose and resume as scheduled.
Consistency matters most in the long run — missing a single dose occasionally has minimal impact on overall efficacy. The most important thing is to maintain a regular weekly schedule going forward.
When a Prescriber May Adjust Your Dose
There are specific clinical situations where a physician may hold, reduce, or delay a dose escalation — or recommend a lower maintenance dose than the maximum approved amount.
Reasons to hold or reduce dose
- Persistent GI side effects that do not improve after 4 weeks at a given dose — nausea, vomiting, or diarrhea that disrupts daily life warrants a conversation with your physician. A dose hold or reduction is common and does not mean the medication isn't working.
- Plateau in weight loss — If you've been at a stable dose for 8–12 weeks without further weight loss, your physician may discuss whether to increase to the next level. Not all patients need to be at the maximum dose to see meaningful results.
- Intolerable side effects at the next step — If 4 weeks of tolerance at 0.5 mg doesn't prepare you well enough for 1 mg, your physician may extend the current dose rather than escalating. The schedule is a guide, not a mandate.
- Other medications or health events — Surgery, fasting, significant illness, or changes in other medications may prompt a temporary dose reduction.
Reasons dose escalation may be appropriate
- Inadequate weight loss response at the current dose — typically assessed after 8–12 weeks at a stable dose
- Good tolerability with insufficient appetite suppression — some patients tolerate higher doses without GI issues but see meaningful benefit from escalation
- HbA1c above target (for Ozempic/Mounjaro in diabetes management) — glycemic control may warrant dose increase even if weight loss is adequate
Your prescribing physician has the clinical context to make these decisions. Never adjust on your own — but do have the conversation if you feel a dose change may be warranted.
For the full clinical picture — including how semaglutide and tirzepatide compare on efficacy, side effects, and cost — see our comparison guide: Ozempic vs Wegovy vs Mounjaro: Which GLP-1 Is Right for You?
Ready to Start or Review Your Current Treatment?
PropPilot physicians assess your complete health profile, explain what to expect at each dose level, and prescribe at the dose that's right for you — all from home, within 24 hours.
Start Free Eligibility AssessmentNo commitment required · Physician-reviewed · Results may vary